Tenghui Chen United States

Cancer Immunotherapy development
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
PepGene Inc
CTO 

Paul Chen China

Reistone BioPharma is a clinical-stage biotech company focused on developing innovative medicines in autoimmune and autoinflammatory diseases. We are headquartered in Shanghai, China and have offices in Beijing, China as well in Boston and Chicago, US. Our current pipeline includes 4 small molecules in autoimmune and inflammatory diseases where significant gaps exist. The leading asset, a potent selective JAK1 inhibitor, recently completed global Phase II trials in China, US and Europe in atopic dermatitis, ulcerative colitis and Crohn’s disease.

Currently we are looking for either partnership to develop the AD and/or UC or CD indications for Phase III or out-license the global right excluding China market.
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Looking to in-license / out-license
Headquartner in China
Biotech/Pharma Asset Stage
Reistone Biopharma
Chief of Staff 
Functionality

Shu Chen

1994年成立上海市国资委直属投资公司
Website:
不对外公开
Partnering Objectives
Headquartner in China
SAIL
投资经理 

Helen Chen

L.E.K. Consulting is a global strategy consulting firm that specializes in corporate strategy, transaction services, and performance improvement. Founded in 1983, we now have more than 1,500 professionals located across major economies worldwide. Clients include Fortune 500, FTSE 100, Eurotop 300, and many of the largest firms in Asia-Pacific.

 

With a reputation for solving the most complex issues, L.E.K. collaborates closely with business leaders and their teams to accelerate the pace and precision of strategic decision-making. L.E.K. works across numerous industry sectors including a strong focus on the healthcare sector.

 

As a leading strategic advisor to the life sciences industry, L.E.K.’s clients include the largest and most advanced pharmaceutical, biotech, medical devices, tools and diagnostics companies. L.E.K.’s global team of life sciences professionals has expertise across all major industry segments and therapeutic areas, and we provide support at each stage of the product life cycle, from drug discovery to commercial optimisation.

 

L.E.K. hosts the Asia Pacific Life Sciences Centre of Excellence in partnership with the Singapore Economic Development Board (“EDB”). This Centre of Excellence (“CoE”) drives thought leadership and innovation to elevate the life sciences ecosystem both in Singapore and across the region.

Website:
www.lek.com
Helen Chen
L.E.K. Consulting
LinkedIn logo Greater China Managing Partner 

Guofeng Cheng China

Biotech
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
AusperBio
CEO 

Mr. Xinwei Cheng United States

Drug delivery antibody gene
Website:
www.luye.com
Company Size (Fulltime employees)
Year of foundation
2012
Partnering Objectives
Please specify your partnering goal
Looking for science and service
Headquartner in China
Luye Boston
Senior Scientists 
Functionality

Mr. Cliff Cheng China

A pharmaceutical company
Website:
www.buchang.com
Company Size (Fulltime employees)
Please specify your partnering goal
licensing-in and partnership
Headquartner in China
Buchang Pharma Group
CSO 

Wei Cheng

Public trade pharmaceutical company
Website:
Www.Fibrogen.com
Partnering Objectives
Headquartner in China
Fibrogen
Executive director 

Changfu Cheng United States

Dear Prospect Customer:

I would like to introduce my company (TDM Pharmaceutical Research, Inc) to you. TDM Pharmaceutical Research, INC, is a highly productive, intensely focused, quality-oriented CRO; we are experienced, well established, and driven by scientific merit. As a full-service GLP and GCP compliant laboratory, TDM offers a variety of discovery, research, development, bioanalytical, and consulting services to support discovery and development of pharmaceutical and chemical products. We pride ourselves on prompt data turnaround and addressing our clients’ needs with the accuracy and quality that are critical to their businesses.

TDM is uniquely different from other CROs: our over 90 years of combined industry experience allows us to resolve complex issues by providing comprehensive solutions in pharmacokinetics, toxicokinetics, pharmacokinetic/pharmacodynamic correlations, and more.

We are experienced in both the sponsor and the CRO position, so we anticipate and address the needs of our clients. Resourceful, committed personnel provide proactive support throughout each project, and respond to potential issues immediately.

Our myriad clients include both companies and individuals in the pharmaceutical and related industries. By selecting TDM as the partner for your next project, you will find we take each job and its needs personally; our focus is always on the client!

If you have any question, please feel free to contact me at: changfu.cheng@tdmrxresearch.com, or phone at 1-774-258-2425.

Thanks!

 

Changfu Cheng, PhD

President

TDM Pharmaceutical Research, Inc

https://tdmpharmalab.com

Company Size (Fulltime employees)
Year of foundation
1996
Please specify your partnering goal
IND of our drug candidates
Headquartner in China
Biotech/Pharma Category
Assets Information 1
FLUORINE- AND/OR DEUTERIUM-CONTAINING COMPOUNDS FOR TREATING NON-SMALL CELL LUNG CANCER AND RELATED DISEASES, US patent 10,633,367
Assets Information 2
DEUTERATED COMPOUNDS FOR TREATING FABRY, GAUCHER, PARKINSON’S AND RELATED DISEASES AND CONDITIONS, AND COMPOSITIONS AND METHODS THEREOF. US patent 10,519,157
Biotech/Pharma Asset Stage
Slides Deck
(pdf, 802.42KB)
TMD Pharmaceutical Research
President 
Functionality

Haipeng Cheng China

Sangel Capital provides venture capital and business finance to support high-tech enterprises in China and US. The firm seeks to invest in innovative startups in sectors including biopharma, diagnostics, medical devices, and biotech.
Sangel Capital was founded in 2010 and is based in Shenzhen, Beijing with additional offices in Suzhou and Chicago.
Sangel Capital